Mylan NV will restructure its global operations, resulting in layoffs that are expected to impact less than 10% of the global work force, the company revealed in a filing with the US Securities & Exchange Commission Dec. 7.
Mylan Plans Workforce Reduction After M&A And Price Scandal
Mylan said it expects to cut less than 10% of its workforce under a restructuring to streamline operations following a series of acquisitions. The news comes amid a spate of negative publicity for the company, including a $465m settlement with the US Department of Justice over EpiPen.
More from Deals
• By
Sanofi sold a 50% stake in consumer health unit Opella for €10bn, backing its shift to prescription drugs and funding a €5bn buyback.
• By
Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.
• By
The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.
• By
Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.
More from Business
• By
The triple therapy improves lung function in the Phase III KALOS and LOGOS studies
• By
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
• By
Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.